Key facts
- It has raised $31.5M; the latest was Later Stage VC ($20.0M) in May 2025.
- Notable investors include Wilson Sonsini Goodrich & Rosati, Anzu Partners, Seed Healthcare.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for BioSkryb Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for BioSkryb Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioSkryb Genomics
Developer of a genome amplification system designed to utilize cellular heterogeneity. The company transforming through its single-cell whole genome and whole transcriptome amplification tools, scientists and clinicians can gain an unprecedented view of the genome, transcriptome and proteome within a single cell to understand the drivers, mechanisms and management of complex diseases and transform single-cell molecular discovery and analysis, enabling medical researchers and clinicians to elucidate the mechanisms of pathology in the genome.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2018
- Employees
- 55
- Website
- bioskryb.com/
- Ownership
- Privately Held (backing)
BioSkryb Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioSkryb Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioSkryb Genomics in its N-PORT filings yet. We sweep new filings monthly.